Changes in compliance with Japanese antiemetic guideline for chemotherapy-induced nausea and vomiting: a nationwide survey using a distributed research network-Reference-Cited by-同舟云学术

Changes in compliance with Japanese antiemetic guideline for chemotherapy-induced nausea and vomiting: a nationwide survey using a distributed research network

Published:2013-11-26 Issue:4 Volume:22 Page:969-977
ISSN:0941-4355
Container-title:Supportive Care in Cancer
language:en
Short-container-title:Support Care Cancer

Author:

Hori Katsuhito,Kobayashi Norihiro,Atsumi Hitoshi,Nagayama Akira,Kondoh Masako,Noge Ichiro,Kimura Midori,Utsugi Hiroaki,Iwasaki Tsuyoshi,Nakamura Masaki,Kimura Tomomi

Publisher

Springer Science and Business Media LLC

Subject

Oncology

Link

http://link.springer.com/content/pdf/10.1007/s00520-013-2048-4.pdf

Reference25 articles.

1. Hilarius DL, Kloeg PH, van der Wall E, van den Heuvel JJ, Gundy CM, Aaronson NK (2012) Chemotherapy-induced nausea and vomiting in daily clinical practice: a community hospital-based study. Support Care Cancer 20(1):107–117. doi: 10.1007/s00520-010-1073-9

2. Hesketh PJ, Grunberg SM, Gralla RJ, Warr DG, Roila F, de Wit R, Chawla SP, Carides AD, Ianus J, Elmer ME, Evans JK, Beck K, Reines S, Horgan KJ (2003) The oral neurokinin-1 antagonist aprepitant for the prevention of chemotherapy-induced nausea and vomiting: a multinational, randomized, double-blind, placebo-controlled trial in patients receiving high-dose cisplatin—the Aprepitant Protocol 052 Study Group. J Clin Oncol 21(22):4112–4119. doi: 10.1200/JCO.2003.01.095

3. Poli-Bigelli S, Rodrigues-Pereira J, Carides AD, Julie Ma G, Eldridge K, Hipple A, Evans JK, Horgan KJ, Lawson F (2003) Addition of the neurokinin 1 receptor antagonist aprepitant to standard antiemetic therapy improves control of chemotherapy-induced nausea and vomiting. Results from a randomized, double-blind, placebo-controlled trial in Latin America. Cancer 97(12):3090–3098. doi: 10.1002/cncr.11433

4. Warr DG, Grunberg SM, Gralla RJ, Hesketh PJ, Roila F, Wit R, Carides AD, Taylor A, Evans JK, Horgan KJ (2005) The oral NK(1) antagonist aprepitant for the prevention of acute and delayed chemotherapy-induced nausea and vomiting: pooled data from 2 randomised, double-blind, placebo controlled trials. Eur J Cancer 41(9):1278–1285

5. Grunberg S, Chua D, Maru A, Dinis J, DeVandry S, Boice JA, Hardwick JS, Beckford E, Taylor A, Carides A, Roila F, Herrstedt J (2011) Single-dose fosaprepitant for the prevention of chemotherapy-induced nausea and vomiting associated with cisplatin therapy: randomized, double-blind study protocol-EASE. J Clin Oncol 29(11):1495–1501. doi: 10.1200/JCO.2010.31.7859

Cited by 13 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Clinical Pharmacology Strategy for Registration in Japan with a Case Example of Posaconazole, a Globally Approved Triazole Antifungal Drug with Broad-spectrum Antifungal Activity;Rinsho yakuri/Japanese Journal of Clinical Pharmacology and Therapeutics;2024-05-31

2. Certified nurse specialists in cancer nursing and prophylactic antiemetic prescription for chemotherapy patients;Supportive Care in Cancer;2022-04-07

3. Protective effect of aprepitant against chemotherapy-induced nausea and vomiting in postoperative chemotherapy for gastric cancer;TROP J PHARM RES;2019

4. Control of Nausea Based on Risk Analysis in Patients with Esophageal and Gastric Cancer Who Received Cisplatin-based Chemotherapy;Anticancer Research;2017-12-03

5. Comparative investigation of the anti-emetic effects of granisetron and palonosetron during the treatment of acute myeloid leukemia;Molecular and Clinical Oncology;2017-07-28